Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

In a new study, researchers analyzed the effect of vaccine booster doses against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

AMSBIO Expands EU Operations

...

From AMS Biotechnology 26 Jan 2022

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

In a study published in the latest issue of the Scientific Reports, a team of researchers constructed virus-like particles (VLPs) composed of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M), envelope (E), and nucleocapsid (N) proteins in tobacco plant using Agrobacterium-mediated delivery.

24 Jan 2022

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

Exploring the interactions between multiple respiratory viruses

A recent report explores the dynamics of viral interference between various respiratory viruses in light of the ongoing COVID-19 pandemic.

19 Jan 2022

Vaccination offers long-term protection from worst outcomes of COVID-19

Vaccination offers long-lasting protection from the worst outcomes of COVID-19, according to a new study by the University of North Carolina at Chapel Hill.

13 Jan 2022

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

The current study examines the role of heterologous vaccination, an area that lacks much clarity.

11 Jan 2022

Levels of infectious SARS-CoV-2 in vaccinated and unvaccinated individuals

A new study assessed the levels of infectious virus (obtained from the nasopharynx) in vaccinated and unvaccinated individuals.

7 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

Novel insight into the immune characteristics of bats

Many studies have indicated that bats are significant reservoirs of innumerable viruses, such as influenza, coronaviruses, and rabies. These studies have also reported that bats predominantly remain asymptomatic or develop mild diseases during viral infections caused by henipaviruses, Ebola virus, coronaviruses, etc.

4 Jan 2022

Oxford researchers demonstrate the feasibility of increasing the speed and volume of vaccine production

The University of Oxford's vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

4 Jan 2022

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

A new study shows that Omicron is more infectious than any of the other variants and that booster vaccines, especially mRNA vaccines, are capable of neutralizing Omicron variants of pseudoviruses.

29 Dec 2021

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

A new study posted to the medRxiv* pre-print server included individuals over 13 years of age receiving the third vaccine dose to further evaluate the association between myocarditis and COVID-19 vaccination or infection. The study took place from December 1, 2020, to November 15, 2021.

28 Dec 2021

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

A new study examines the impact of the Omicron variant on hospitalizations among children in South Africa.

23 Dec 2021

How COVID vaccines protected Americans against the Delta variant

A new study analyzed the COVID-19 breakthrough case and death rates among fully vaccinated individuals who were 12 years of age or above.

22 Dec 2021

Researchers identify new mechanism for DNA invasion of adenoviral COVID-19 vaccines

Adenoviruses have a linchpin protein that stabilizes their DNA until it reaches the infected cell's nucleus. The protein then detaches from the viral genome, and the virus uncoats. Only then are the genes released into the nucleus, which is necessary for the production of new viruses.